• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Using Dental Pulp Stem Cells for Stroke Therapy
Conclusion and Future Perspectives Stem cell-based therapy is a promising alternative for stroke treatment. While stem cells from different sources, including induced PSC, ESC, MSC, and NSC, have been investigated, using NSC and enhancing the natural mechanisms is most appropriate for brain repair. In preclinical models of stroke, stem cell transplantation has led to positive outcomes through a variety of cellular and molecular mechanisms, many being mediated by the array of beneficial factors produced by the cells. Recent advances in cellular reprogramming have provided alternative sources of NSC to be investigated, allo...
Source: Frontiers in Neurology - April 28, 2019 Category: Neurology Source Type: research

Modafinil for the Improvement of Patient Outcomes Following Traumatic Brain Injury
Conclusion. Modafinil is a central nervous system stimulant with well-established effectiveness in the treatment of narcolepsy and shift-work sleep disorder. There is conflicting evidence about the benefits of modafinil in the treatment of fatigue and EDS secondary to TBI. One randomized, controlled study states that modafinil does not significantly improve patient wakefulness, while another concludes that modafinil corrects EDS but not fatigue. An observational study provides evidence that modafinil increases alertness in fatigued patients with past medical history of brainstem diencephalic stroke or multiple sclerosis. ...
Source: Innovations in Clinical Neuroscience - April 1, 2018 Category: Neuroscience Authors: ICNS Online Editor Tags: Current Issue Review excessive daytime sleep fatigue head injury modafinil stroke TBI traumatic brain injury Source Type: research

Regional Differences in Early BP Management After Acute Ischemic Stroke in the ENCHANTED International Randomized Controlled Trials
Conclusion: Regional variations in early BP management in acute stroke translated into differences in early BP control parameters.
Source: Frontiers in Neurology - August 27, 2021 Category: Neurology Source Type: research

Transcranial Direct Current Stimulation Use in Warfighting: Benefits, Risks, and Future Prospects
Conclusion The aim of this paper was to examine whether military tDCS use can be efficacious and ethical in military settings. Our assessment is that tDCS offers a number of cognitive, motor, and perceptual enhancement opportunities which could provide value in military situations like training and operations. There is potential scope for use in a number of key areas that directly affect practical battlefield advantage and survivability, such as deceptive capabilities, risk-taking, threat detection, perception, and physiological improvement. Additionally, tDCS has the potential to improve command and control decision maki...
Source: Frontiers in Human Neuroscience - April 17, 2019 Category: Neuroscience Source Type: research

EE352 Projecting the Incidence and Costs of Major Cardiorenal Complications of Type 2 Diabetes with Widespread GLP-1 RA and SGLT2I Use
Whether glucagon-like peptide-1 receptor agonists (GLP-1 RAs) or sodium-glucose co-transporter 2 inhibitors (SGLT2is) are cost-effective when considering solely their cardiorenal benefits is unknown. We projected the incidence and costs of hospitalisation for myocardial infarction (MI), stroke, and heart failure (HF), and end-stage kidney disease (ESKD) among people with type 2 diabetes under scenarios of widespread use of these drugs, from an Australian healthcare perspective.
Source: Value in Health - June 26, 2022 Category: International Medicine & Public Health Authors: J Morton, C Marquina, JE Shaw, D Liew, Z Ademi, D Magliano Source Type: research

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
Conclusions/interpretationAt current prices, use of SGLT2is, but not GLP-1 RAs, would be cost-effective when considering only their cardiovascular and kidney disease benefits for people with type 2 diabetes.Graphical abstract
Source: Diabetologia - February 22, 2023 Category: Endocrinology Source Type: research